Astria Therapeutics, Inc. announced on September 3, 2025, that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025. The congress is scheduled to take place from September 17-20, 2025, in Paris, France.
STAR-0310 is a monoclonal antibody OX40 antagonist in development for the treatment of atopic dermatitis (AD). The upcoming presentation of initial Phase 1a data is a highly anticipated event, as it will provide the first clinical insights into the safety, tolerability, pharmacokinetics, and immunogenicity of this investigational therapy in healthy subjects.
This data readout is crucial for informing the future development strategy for STAR-0310 and could further differentiate its profile in the competitive AD landscape. Investors and the medical community will be closely watching for results that support its potential as a best-in-class OX40 antagonist with infrequent dosing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.